CUD
How a Soft Diagnosis Becomes a Hard Headline
Two of eleven. That's the entire bar for a diagnosis now making headlines as "cannabis addiction."
Marijuana.com.au Policy Research Desk.
An independent editorial desk tracking Australian medicinal cannabis policy, TGA frameworks, and patient civil liberties since 1999.
CUD
New Genetics Study Splits "Cannabis Use" From "Cannabis Use Disorder"
Roughly one in ten people who try cannabis goes on to develop cannabis use disorder (CUD). What separates that minority from everyone else who uses cannabis without it becoming a problem has never been well understood.
OPINION
The Chronic Illness Trap: Why NSW’s New Medical Cannabis Driving Laws Are a Backdoor Ban
These changes do not liberate medicinal cannabis users; instead, they establish a digital surveillance framework that explicitly targets and bans people with chronic illnesses from driving.
The Study Said Psychosis Rates Were Equal to Placebo. Most Outlets Left That Part Out.
A major Lancet Psychiatry meta-analysis on cannabinoids and mental health was reported accurately on some points, incompletely on others, and misleadingly on at least one finding that cuts against a well-established media narrative. Often, all three occurred in the same article.`
hemp
Running on Empty: Why Hemp Derived Biodiesel Deserves a Serious Place in Australia's Fuel Future
"Australia cannot refinery-build its way out of this crisis quickly enough. But it can grow its way toward a more resilient position — if it chooses to."
Alzheimers
New Preclinical Research Explores the Endocannabinoid System in Alzheimer's Disease and Chronic Pain
The endocannabinoid system plays a modulatory role in both pain processing and neurological function. It is altered in both Alzheimer's disease and chronic pain states, making it an area of active research interest.
RPBS
Two Veterans, Same Diagnosis, Different Rules: DVA's New Medicinal Cannabis Framework Creates a Two-Tier System
For a veteran in outback Queensland newly diagnosed with a terminal illness, "find a specialist and attend in person first" is not a neutral administrative requirement. It is a genuine barrier to care, arriving at the worst possible time.
study
Cannabis Shows Promise for Advanced Pancreatic Cancer Symptom Management
The study was supported by philanthropic funding to the HealthPartners Cancer Research Centre, with cannabis products provided by Vireo Health (GreenGoods, Minnesota).
Legalise Cannabis Australia
Victorian Medicinal Cannabis Driving Trial Reaches Key Milestone
Recruitment of adults with medicinal cannabis prescriptions has now concluded.
Trump
Trump Executive Order Signals Major Shift in US Medical Cannabis Policy
Schedule III classification would recognise cannabis as having accepted medical use and lower abuse potential than Schedule I or II substances.
medical cannabis
New York Study Links Medical Cannabis to Reduced Opioid Use
The 22% reduction in opioid use may seem modest, but researchers emphasise this aligns with current clinical recommendations for gradual opioid tapering over extended periods rather than rapid cessation.
hemp
Australia's Hemp Trials Reveal Hard Truths: Industry at Critical Crossroads
The most alarming finding from the trials is the catastrophic variability in imported seed quality.
hyperspectral
Early Leaf Scans Could Revolutionise Cannabis Production
The implications for Australia's emerging cannabis industry are substantial.
Sativex
CNX Therapeutics Acquires Sativex in Strategic CNS Portfolio Expansion
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
OPINION
The Cannabis Paradox: How Australia's Medical Market Boom Became a Domestic Industry Crisis
The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.
Cann Group
Cann Group Secures Major Debt Restructure and $9M Capital Raise
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.